OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2025.14926 OL-29-4-14926 Articles Prognostic value of preoperative modified Glasgow prognostic score in predicting overall survival in breast cancer patients: A retrospective cohort study ChenYi 1 2 * ZhangBoxiang 1 2 * WangXiaoli 1 2 * ChenYanyan 1 2 AnwarMunawar 1 2 FanJingjing 1 2 MaBinlin 1 2 Department of Breast and Thyroid Surgery, The Affiliated Cancer Hospital of Xinjiang Medical University, Xinjiang Key Laboratory of Oncology, Urumqi, Xinjiang Uygur Autonomous Region 830011, P.R. China The Clinical Medical Research Center of Breast and Thyroid Tumor in Xinjiang, Urumqi, Xinjiang Uygur Autonomous Region 830011, P. R. China Correspondence to: Dr Jingjing Fan or Professor Binlin Ma, Department of Breast and Thyroid Surgery, The Affiliated Cancer Hospital of Xinjiang Medical University, Xinjiang Key Laboratory of Oncology, 789 Suzhou East Street, Xinshi, Urumqi, Xinjiang Uygur Autonomous Region 830011, P.R. China, E-mail: fjjsunny@163.com mbldoctor@126.com

Contributed equally

 04 2025 11 02 2025 29 4 180 22102024 07012025 Copyright: © 2025 Chen et al. 2025 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The modified Glasgow prognostic score (mGPS), based on C-reactive protein and albumin levels, is an inflammation-based prognostic tool used in various cancers. However, related research in breast cancer is limited. The present study evaluated the prognostic value of the preoperative mGPS in predicting overall survival (OS) of patients with breast cancer undergoing surgery. A retrospective cohort study was conducted involving 300 patients with breast cancer with up to 10 years of follow-up. Patients were categorized into three groups based on mGPS scores of 0, 1 and 2, and their clinical and pathological data were collected. Kaplan-Meier survival analysis and Cox proportional hazards models were used to assess survival outcomes and identify risk factors associated with higher mGPS scores. A prognostic nomogram was developed based on multivariate analysis to predict 5- and 10-year OS. Patients with high mGPS scores showed significantly poor survival outcomes. The 5- and 10-year survival rates for mGPS 0, 1 and 2 were 80, 70 and 55%, and 71, 55 and 22%, respectively (P<0.001). Multivariate Cox analysis identified the mGPS, age, smoking, PAM50 and TNM stage as independent predictors of OS. The nomogram based on the mGPS demonstrated good predictive accuracy (concordance index: 0.81) and calibration. The preoperative mGPS is an independent prognostic factor for OS of patients with breast cancer. It is a simple, cost-effective tool that can aid in risk stratification and guide treatment strategies. Further validation in larger cohorts is recommended.

 breast cancer modified Glasgow prognostic score overall survival prognostic biomarker nomogram National Natural Science Foundation of China 82260549 This study was supported by the National Natural Science Foundation of China (grant no. 82260549). Introduction

Breast cancer is the most commonly diagnosed cancer among women worldwide and remains a leading cause of cancer-related mortality. Despite advancements in early detection and treatment strategies, the prognosis of breast cancer varies significantly due to its heterogeneous nature and the complex interactions between tumor biology and the host immune response (1). Identifying reliable prognostic factors is essential for personalized treatment and management, which can improve survival outcomes and the quality of life of patients with breast cancer (2).

Inflammation has a crucial role in cancer development, progression and response to treatment (3). The modified Glasgow prognostic score (mGPS), a systemic inflammation-based scoring system, has emerged as a valuable prognostic tool for various cancers (4). The mGPS is derived from two widely accessible biomarkers: C-reactive protein (CRP) and albumin (Alb) levels. A score of 0 indicates a low mGPS, representing normal CRP (≤10 mg/l) and Alb (≥35 g/l) levels. Scores of 1 and 2 correspond to high mGPS, indicating elevated CRP levels (>10 mg/l) with normal or decreased Alb levels, respectively. This simple, non-invasive scoring system has been validated in various cancer types, including prostate, gynecological, lung and colorectal cancers, showing a consistent association with poor survival outcomes (5–10). However, its prognostic utility in breast cancer remains underexplored.

Recent studies suggest that systemic inflammation influences the tumor microenvironment and may modulate immune surveillance and therapeutic response. Elevated CRP levels are indicative of chronic inflammation, while hypoalbuminemia reflects malnutrition and systemic inflammation, both of which can impair the host's ability to mount an effective anti-tumor response (11–14). Given that breast cancer subtypes, such as triple-negative breast cancer (TNBC), have distinct molecular profiles and immune characteristics, understanding the predictive value of mGPS across these subtypes is crucial for its clinical applicability.

In breast cancer, several established prognostic factors include tumor size, lymph node status, histological grade, hormone receptor status, human epidermal growth factor receptor 2 (HER2) status and 50-gene intrinsic subtype classifier (PAM50) subtypes (15–17). However, these factors primarily focus on tumor biology and do not account for the systemic inflammatory response. By integrating mGPS with these traditional prognostic markers, it is possible to develop a more comprehensive risk stratification model that reflects both tumor and host-related factors. This approach may offer better predictive accuracy for OS and aid in tailoring therapeutic interventions for different patient groups.

The current study aims to evaluate the prognostic value of the preoperative mGPS in patients with breast cancer undergoing surgery. A retrospective analysis of 300 patients with breast cancer who underwent surgery and were followed for up to 10 years was conducted. The association between preoperative mGPS and long-term survival outcomes was assessed using a variety of statistical methods, including Kaplan-Meier survival analysis, logistic regression and Cox proportional hazards models. In addition, a nomogram based on significant factors identified in a multivariate analysis was constructed to predict 5- and 10-year OS. By analyzing the impact of mGPS on breast cancer prognosis, the present study aimed to provide insights into its potential role as an independent predictor of survival. This study also seeks to establish whether mGPS, when combined with established clinical and pathological factors, can improve risk stratification and guide personalized treatment planning. The findings of this study may help integrate mGPS into routine clinical practice as a simple, accessible and effective prognostic tool for patients with breast cancer.

 Patients and methods <sec> <title>Patients

The present study is a retrospective cohort analysis conducted on patients with breast cancer who underwent surgical treatment at the Affiliated Cancer Hospital of Xinjiang Medical University (Urumqi, China) from January 2013 to January 2014. A total of 300 patients were included based on the following criteria: i) Histologically confirmed breast cancer; ii) available preoperative CRP and Alb levels for mGPS calculation; iii) complete clinicopathological data; and iv) a follow-up period of at least five years. Patients with concurrent inflammatory diseases or autoimmune conditions, or those receiving immunosuppressive therapy were excluded to minimize confounding factors that may influence systemic inflammation levels. The inclusion of 300 consecutive patients within this one-year period was based on the hospital's annual surgical caseload for breast cancer during this timeframe. Given the large number of breast cancer surgeries conducted at the hospital annually, this cohort provided an adequate sample size to conduct meaningful survival analysis while reflecting the real-world clinical setting. This period allowed for comprehensive follow-up data collection (up to 10 years) and ensured consistency in treatment protocols during that time. Therefore, this cohort size and timeframe were appropriate to investigate the prognostic value of preoperative mGPS in patients with breast cancer. Among the enrolled patients, a subset of patients with stage IV breast cancer was included. Typically, patients with stage IV breast cancer, due to distant metastasis, are not candidates for curative surgery. However, certain patients with stage IV in this study underwent palliative surgery, primarily to alleviate symptoms or control the primary tumor. These surgeries were conducted in conjunction with other treatments, such as chemotherapy, targeted therapy or endocrine therapy. The surgeries were not aimed at curing the disease but at improving the patients' quality of life or addressing local complications caused by the primary tumor. All patients, including those with stage IV disease, underwent comprehensive clinical evaluation prior to surgery. The decision to proceed with surgery was made by a multidisciplinary team, considering the patient's overall health, response to previous treatments and symptom burden. The inclusion of patients with stage IV in the present study was intended to explore the OS and prognostic factors associated with breast cancer, with a focus on evaluating the role of the mGPS as a prognostic tool. It is acknowledged that patients with stage IV typically have a shorter survival period, but their inclusion helps assess the prognostic predictive value of the mGPS across different stages of breast cancer.

 Data collection

Clinical and pathological data were retrieved from the electronic medical records of each patient. Collected variables included age, body mass index (BMI), smoking status, alcohol consumption, diabetes status, hypertension, family history of breast cancer, TNM stage (18) and PAM50 molecular subtype (19). Treatment modalities, including endocrine therapy, targeted therapy, chemotherapy and immunotherapy, were also documented. All patients provided informed consent prior to data collection and the study was approved by the Ethics Committee of the Affiliated Cancer Hospital of Xinjiang Medical University (Urumqi, China; approval no. K-2024056) in accordance with the Declaration of Helsinki.

 mGPS calculation

The mGPS was calculated based on preoperative CRP and serum Alb levels. A score of 0 was assigned if CRP levels were ≤10 mg/l and Alb levels were ≥35 g/l. A score of 1 was assigned if CRP levels were >10 mg/l with Alb levels ≥35 g/l. A score of 2 was assigned if CRP levels were >10 mg/l and Alb levels <35 g/l. Patients were stratified into three groups based on their mGPS: mGPS 0 (108 patients), mGPS 1 (120 patients) and mGPS 2 (72 patients), as shown in Table I. This stratification allowed for comparison of clinical outcomes across different mGPS categories.

 Statistical analysis

All statistical analyses were conducted using SPSS software (version 29.0; IBM Corp.) and R software (version 4.0.3; R Foundation for Statistical Computing). P<0.05 was considered to indicate statistical significance. Baseline characteristics: Descriptive statistics were used to summarize the clinical and pathological characteristics of the study population. Continuous variables (e.g., age, BMI) were expressed as the mean ± standard deviation and compared across mGPS groups using one-way ANOVA, after confirming the normality of the data using the Shapiro-Wilk test. If the data did not meet the normality assumption, the Kruskal-Wallis H-test was used as an alternative. For post-hoc analysis, Tukey's Honestly Significant Difference test was applied to identify specific group differences. Categorical variables (e.g., smoking, drinking, TNM stage, PAM50 subtype) were expressed as frequencies and percentages and compared using the Chi-square test or Fisher's exact test, as appropriate. Kaplan-Meier survival analysis: OS was defined as the time from the date of surgery to the date of death from any cause or the last follow-up. Patients lost to follow-up were censored at the time of the last available follow-up. Censoring refers to the inclusion of individuals who did not experience the event of interest (death) by the end of the study period or at the time they were lost to follow-up. Kaplan-Meier survival curves were generated to evaluate the OS of patients in the mGPS 0, 1 and 2 groups. The log-rank test was applied to compare survival differences among the groups. The 5- and 10-year survival rates were recorded for each mGPS category. Logistic regression analysis: To identify factors associated with higher mGPS scores, a univariate logistic regression analysis was performed for each clinical and pathological variable, including age, BMI, smoking status, alcohol consumption, diabetes, hypertension, TNM stage and PAM50 subtype. Variables with a P<0.05 in the univariate analysis were subsequently included in a multivariate logistic regression model. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using logistic regression analysis to determine the independent risk factors for higher mGPS scores, adjusting for potential confounders such as age, sex, disease stage, and treatment modalities. Cox proportional hazards regression analysis: Univariate and multivariate Cox proportional hazards regression models were used to assess the association between mGPS and OS. Clinical and pathological variables and mGPS scores were first analyzed individually to determine their hazard ratios (HRs) for OS. Variables with P<0.05 in the univariate analysis were included in the multivariate analysis. The multivariate model adjusted for potential confounders to identify independent predictors of OS. Nomogram and calibration curve: A nomogram was constructed based on the results of the multivariate Cox regression analysis to predict the 5- and 10-year OS of patients. The nomogram incorporated the most significant prognostic factors, including age, smoking status, TNM stage, PAM50 subtype and mGPS score. The nomogram's predictive accuracy was evaluated using Harrell's C-index. Calibration curves were plotted to assess the agreement between predicted survival probabilities and observed outcomes using bootstrapped resampling (1,000 repetitions) for internal validation.

 Results <sec> <title>Patient characteristics and differences across mGPS groups

A total of 300 patients with breast cancer were included in the present study. The mean age of the patients was 51.3 years (range, 34–78 years). All patients were female. Patients were categorized into three groups based on their preoperative mGPS: mGPS 0 (n=108), mGPS 1 (n=120) and mGPS 2 (n=72). The baseline characteristics of the patients are summarized in Table II. Significant differences were observed among the three mGPS groups in terms of age (P<0.001), BMI (P=0.011), smoking status (P<0.001), alcohol consumption (P=0.027), diabetes (P=0.026), TNM stage (P=0.001) and PAM50 molecular subtype (P=0.047). Specifically, higher mGPS scores were associated with older age, higher BMI, smoking and drinking history, advanced TNM stage and TNBC subtype. No significant differences were found for hypertension, family history of breast cancer or treatment modalities (endocrine therapy, targeted therapy, chemotherapy and immunotherapy) (P>0.05 for all).

 High mGPS scores are associated with poor survival outcomes

The Kaplan-Meier survival curves for the three mGPS groups are shown in Fig. 1. The 5-year survival rates were 80, 70 and 55% for the mGPS 0, mGPS 1 and mGPS 2 groups, respectively. The 10-year survival rates were 71, 55 and 22% for these groups. The log-rank test revealed a significant difference in OS among the three groups (P<0.001). Further pairwise comparisons showed significant differences between the following groups: mGPS 0 vs. mGPS 1 (P<0.001), mGPS 1 vs. mGPS 2 (P=0.025) and mGPS 0 vs. mGPS 2 (P<0.001). Patients with higher mGPS scores had significantly poorer survival outcomes compared to those with lower scores. Specifically, the mGPS 2 group demonstrated the worst survival rates, highlighting the association between higher mGPS scores and reduced survival.

 Risk factors associated with high mGPS scores

To identify clinical and pathological factors associated with high mGPS scores, logistic regression analysis was performed. In the univariate analysis (Table III), factors significantly associated with increased mGPS scores included age ≥65 years (OR: 2.836, 95% CI: 1.783–4.545, P<0.001), smoking (OR: 3.214, 95% CI: 1.948–5.267, P<0.001), drinking (OR: 2.180, 95% CI: 1.355–3.486, P=0.002), TNM stage III (OR: 3.145, 95% CI: 1.358–5.765, P<0.001), TNM stage IV (OR: 4.832, 95% CI: 3.227–8.906, P<0.001) and TNBC subtype (OR: 3.123, 95% CI: 1.858–5.251, P<0.001). These variables were included in the multivariate logistic regression model, which confirmed that age ≥65 years (OR: 1.126, 95% CI: 1.091–1.172, P<0.001), smoking (OR: 1.395, 95% CI: 1.152–2.102, P=0.008), drinking (OR: 1.477, 95% CI: 1.268–2.669, P=0.002), TNM stage III (OR: 1.351, 95% CI: 1.185–1.925, P=0.010), TNM stage IV (OR: 2.005, 95% CI: 1.314–7.275, P<0.001) and TNBC subtype (OR: 2.173, 95% CI: 1.683–3.555, P=0.002) were independent risk factors for higher mGPS scores (Fig. 2).

 mGPS is an independent predictor for OS in breast cancer

To evaluate the impact of clinical characteristics and the mGPS on OS, univariate and multivariate Cox proportional hazards regression analyses were conducted. In the univariate analysis (Table IV), several factors were associated with a higher risk of mortality, including age ≥65 years (HR: 3.376, 95% CI: 1.227–5.258, P<0.001), smoking (HR: 2.045, 95% CI: 1.183–4.904, P=0.001), drinking (HR: 1.762, 95% CI: 1.254–3.255, P=0.004), family history (HR: 1.827, 95% CI: 1.374–3.359, P=0.025), TNM stage III (HR: 2.659, 95% CI: 1.517–5.043, P=0.031), TNM stage IV (HR: 4.274, 95% CI: 2.654–7.268, P<0.001), TNBC subtype (HR: 3.053, 95% CI: 2.073–6.383, P<0.001) and mGPS scores of 1 (HR: 2.622, 95% CI: 1.674–5.538, P=0.001) and 2 (HR: 4.139, 95% CI: 2.822–9.163, P<0.001). In the multivariate Cox analysis, after adjusting for confounders such as age, BMI and PAM50 subtype, the mGPS score remained a significant independent predictor of OS. Patients with mGPS 1 had an HR of 1.322 (95% CI: 1.086–1.713, P=0.012) and those with mGPS 2 had an HR of 2.056 (95% CI: 1.751–4.322, P<0.001) when compared to patients with mGPS 0. Age ≥65 years (HR: 1.212, 95% CI: 1.132–1.455, P=0.001), smoking (HR: 1.173, 95% CI: 1.052–1.603, P=0.013), TNM stage III (HR: 1.114, 95% CI: 1.005–1.252, P=0.022), TNM stage IV (HR: 1.353, 95% CI: 1.157–1.776, P<0.001) and TNBC subtype (HR: 1.449, 95% CI: 1.257–1.748, P=0.038) were also independent predictors of worse OS (Fig. 3).

 Nomogram based on mGPS accurately predicts survival

Based on the multivariate Cox regression model, a prognostic nomogram was developed incorporating age, smoking status, TNM stage, PAM50 subtype and mGPS score to predict 5- and 10-year OS (Fig. 4). The nomogram demonstrated good predictive accuracy with a concordance index of 0.81 (95% CI: 0.75–0.88). Calibration curves showed strong agreement between the predicted and observed survival rates, indicating the model's robustness and applicability in clinical practice. For internal validation, bootstrapped resampling (1,000 repetitions) was performed, confirming the reliability of the nomogram.

 Discussion

This study aimed to evaluate the prognostic value of the preoperative mGPS in patients with breast cancer undergoing surgery. The present findings firstly demonstrated that higher mGPS scores are significantly associated with poorer OS of patients with breast cancer, independent of other established clinical and pathological factors. This suggests that mGPS, a simple and cost-effective biomarker of systemic inflammation, may serve as an effective prognostic tool in clinical practice for patients with breast cancer.

Inflammation is increasingly recognized as a critical factor in cancer development and progression. The mGPS, based on serum CRP and Alb levels, reflects systemic inflammation and nutritional status. Elevated CRP levels indicate a pro-inflammatory state, while hypoalbuminemia reflects both malnutrition and inflammation (20,21). These factors may collectively impair the host's anti-tumor response and promote tumor progression. The current findings align with previous studies demonstrating that high mGPS scores are associated with poor prognosis in several cancers, including colorectal, lung and gastric cancers (22–27). The present study extends the prognostic utility of mGPS to breast cancer, showing that higher mGPS scores are associated with significantly lower 5- and 10-year survival rates.

Traditional prognostic markers for breast cancer, such as tumor size, lymph node status, hormone receptor status, HER2 status and PAM50 molecular subtype, primarily focus on the tumor itself (28). However, these markers do not capture the host's systemic response to the tumor, which is an important determinant of patient outcomes (29). By integrating the mGPS into the prognostic assessment, clinicians may obtain a more comprehensive picture that includes both tumor characteristics and the host's inflammatory and nutritional status. The present multivariate analysis confirms that the mGPS is an independent predictor of OS, even after adjusting for other factors such as TNM stage, age and PAM50 subtype. This suggests that incorporating the mGPS into existing risk models may enhance their predictive accuracy and provide additional information for personalized treatment planning.

The biological mechanisms underlying the association between a high mGPS and poor prognosis in breast cancer likely involve several pathways. Chronic inflammation, as indicated by elevated CRP levels, is known to promote tumor growth, angiogenesis and metastasis (30). Inflammatory cytokines such as interleukin-6 and tumor necrosis factor-α can create a tumor-promoting environment by enhancing cell proliferation and inhibiting apoptosis (31–33). In addition, systemic inflammation may lead to immunosuppression, reducing the effectiveness of the body's immune surveillance against tumor cells (34). Furthermore, hypoalbuminemia, a component of the mGPS, may indicate malnutrition or an advanced inflammatory state, both of which are associated with poorer outcomes in cancer patients. Alb has antioxidant properties and plays a role in maintaining oncotic pressure and drug binding; its reduction may contribute to poorer clinical conditions and reduced efficacy of therapies (35–37). The combination of elevated CRP and low Alb in the mGPS scoring system may therefore capture a more comprehensive picture of a patient's inflammatory and nutritional status, which is crucial in understanding breast cancer prognosis.

Although the present study demonstrates the independent prognostic value of the preoperative mGPS in assessing the prognosis of patients with breast cancer, it is important to acknowledge the limitations of this scoring system. First, mGPS only considers two factors-systemic inflammation and nutritional status- and does not account for other key factors that may affect the prognosis of patients with breast cancer, such as the tumor microenvironment, immune cell infiltration and genetic mutations or molecular characteristics. For instance, molecular subtypes of breast cancer (e.g., TNBC) and the HER2+ status have been shown to be closely related to survival outcomes (38), but these factors are not included in the mGPS. Therefore, the mGPS should be considered a supplementary tool for prognostic evaluation rather than the sole prognostic criterion. Secondly, as a blood biomarker-based tool, the mGPS does not reflect the local tumor characteristics or changes in other clinical factors. Over the follow-up period, patients with breast cancer may experience various events that impact survival, including recurrence, metastasis and treatment-related side effects, none of which are captured by the mGPS. Thus, the mGPS can only provide a snapshot of the patient's overall health status and cannot fully replace real-time monitoring of tumor dynamics. In addition, because the present study is a retrospective cohort analysis, the quality and completeness of the data collection may be influenced by the patients' medical records and follow-up data. Although efforts were made to control potential confounding factors through strict inclusion criteria and multivariate adjustments, it is impossible to rule out the possibility that certain important clinical information was not recorded or considered in the real clinical environment. The present study was conducted at a single institution, which may limit the generalizability of the current findings. Future prospective studies involving multiple centers and larger patient populations are needed to validate the present results and explore the potential role of mGPS in guiding treatment decisions. One of the limitations of the present study is the inability to monitor the impact of certain factors, such as the patient's age, the occurrence of other diseases during the 10-year follow-up period and the recurrence of breast cancer, on survival outcomes. However, considering that the preoperative mGPS was used in this study, this limitation may not apply to the preoperative prognosis, as the factors mentioned here typically occur later during the follow-up period, after the initial surgery. Therefore, these factors are more relevant to predicting postoperative survival outcomes, rather than affecting the preoperative prognosis assessed by the mGPS. These factors can significantly influence prognosis and may have confounded the relationship between mGPS scores and OS. Although the analysis controlled for known clinical variables, such as TNM stage and PAM50 subtype, the long-term nature of the follow-up and the lack of detailed data on these additional factors pose a limitation to the present findings. Future prospective studies should aim to comprehensively monitor these variables to better understand their effects on the survival of patients with breast cancer. Finally, there are inherent limitations to the mGPS itself. For instance, CRP and albumin levels are influenced by numerous non-cancer-related factors, such as infection, surgical trauma and other chronic diseases, which may lead to bias in the mGPS score. While patients with immunosuppressive therapy or inflammatory diseases were excluded, further validation of the stability and reliability of the mGPS in different clinical contexts is still needed. In conclusion, while the mGPS is a simple and cost-effective prognostic tool, its clinical application in breast cancer should be combined with other clinical and pathological features to provide a more comprehensive and accurate survival prediction. Therefore, it is recommended that in clinical practice, the mGPS should be used alongside other molecular biomarkers, immunological indicators and tumor microenvironment characteristics to further improve the accuracy of prognostic assessments and the precision of personalized treatment.

In conclusion, this study was the first to investigate the impact of the preoperative mGPS on the long-term prognosis of patients with breast cancer, with follow-up extending up to 10 years. The current findings show that the mGPS is an independent predictor of OS, with a higher mGPS associated with significantly poorer 5- and 10-year survival rates. Combining the mGPS with other clinical and pathological factors provides an effective risk stratification tool for guiding personalized treatment and follow-up strategies. Future studies should validate these results in larger cohorts and explore mGPS-targeted interventions to improve patient outcomes.

 Acknowledgements

Not applicable.

 Availability of data and materials

The data generated in the present study may be requested from the corresponding author.

 Authors' contributions

JJF and BLM contributed to the conception and design of the study. YC, BXZ and XLW, MA and YYC collected and analyzed data. YC and BXZ wrote and revised the manuscript. BXZ and YYC confirm the authenticity of all the raw data. All authors read and approved the final manuscript.

 Ethics approval and consent to participate

This study was approved by the Ethics Committee of the Affiliated Cancer Hospital of Xinjiang Medical University (Urumqi, China; approval no. K-2024056) in accordance with the Declaration of Helsinki. All of the patients had signed a written informed consent form, which included consent to participate in the study, use of their medical data for research purposes and the publication of anonymized findings.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 Abbreviations mGPS

modified Glasgow prognostic score

 CRP

C-reactive protein

 Alb

albumin

 OS

overall survival

 TNM

tumor-node-metastasis

 PAM50

50-gene intrinsic subtype classifier

 ER

estrogen receptor

 PR

progesterone receptor

 HER2

human epidermal growth factor receptor 2

 TNBC

triple-negative breast cancer

 HR

hazard ratio

 OR

odds ratio

 C-index

concordance index

 CI

confidence interval

 BMI

body mass index

 References NguyenHMPaulishakWOladejoMWoodLDynamic tumor microenvironment, molecular heterogeneity, and distinct immunologic portrait of triple-negative breast cancer: An impact on classification and treatment approachesBreast Cancer30167186202310.1007/s12282-022-01415-436399321 MolinelliCJacobsFAgostinettoENader-MartaGCeppiMBruzzoneMBlondeauxESchettiniFPratAVialeGPrognostic value of HER2-low status in breast cancer: A systematic review and meta-analysisESMO Open8101592202310.1016/j.esmoop.2023.10159237413762 QiXQiaoBSongTHuangDZhangHLiuYJinQYangMLiuDClinical utility of the pan-immune-inflammation value in breast cancer patientsFront Oncol131223786202310.3389/fonc.2023.122378637711203 ZhangYChenSChenHLiWA comprehensive analysis of Glasgow Prognostic Score (GPS)/the modified Glasgow Prognostic Score (mGPS) on immune checkpoint inhibitor efficacy among patients with advanced cancerCancer Med123848202310.1002/cam4.494035702873 ZhangFWuZSunSFuYChenYLiuJPOEMS syndrome in the 21st century: A bibliometric analysisHeliyon9e20612202310.1016/j.heliyon.2023.e2061237842561 ZhangHGaoYYingJYuHGuoRXiongJJiangHBibliometric analysis of global research on breast reconstruction after mastectomy for breast cancer from 2011 to 2021J Cosmet Dermatol2220712082202310.1111/jocd.1568336847708 NieDZhangLWangCGuoQMaoXA high Glasgow prognostic score (GPS) or modified Glasgow prognostic score (mGPS) predicts poor prognosis in gynecologic cancers: A systematic review and meta-analysisArch Gynecol Obstet30115431551202010.1007/s00404-020-05581-832409927 AbbassTDolanRDMacLeodNHorganPGLairdBJMcMillanDCComparison of the prognostic value of MUST, ECOG-PS, mGPS and CT derived body composition analysis in patients with advanced lung cancerClin Nutr ESPEN40349356202010.1016/j.clnesp.2020.08.00333183562 WuZChenYYuGMaYResearch trends and hotspots in surgical treatment of recurrent nasopharyngeal carcinoma: A bibliometric analysis from 2000 to 2023Asian J Surg4729392941202410.1016/j.asjsur.2024.02.10638431480 ZhangHJiaLGuoRXiongJJiangHA bibliometric and visualized study on global trends of breast augmentation complications, 2011–2021Gland Surg12354365202310.21037/gs-22-49937057044 BoukovalaMModestDPRicardIFischer von WeikersthalLDeckerTVehling-KaiserUUhligJSchenkMFreiberg-RichterJPeuserBEvaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: A post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)ESMO Open9103374202410.1016/j.esmoop.2024.10337438744100 Goktas AydinSKutluYMugluHAydinAAcikgozOHamdardJKarciEBiliciAOlmezOFYildizOPredictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamideCancer Chemother Pharmacol937178202410.1007/s00280-023-04592-x37773537 LiJWuZPanYChenYChuJCongYFangQGNL3L exhibits pro-tumor activities via NF-κB pathway as a poor prognostic factor in acute myeloid leukemiaJ Cancer1540724080202410.7150/jca.9533938947394 ZhangHTangSBiskupEZhangYYongLChenLCaiFLong-term survival after diverse therapeutic modalities in malignant phyllodes tumors of the breastTechnol Cancer Res Treat2115330338221121086202210.1177/1533033822112108636000314 LiuXYZhangXZhangQRuanGTLiuTXieHLGeYZSongMMDengLShiHPThe value of CRP-albumin-lymphocyte index (CALLY index) as a prognostic biomarker in patients with non-small cell lung cancerSupport Care Cancer31533202310.1007/s00520-023-07997-937610445 Di CastelnuovoABonaccioMCostanzoSDe CurtisAMagnaccaSPersichilloMPanzeraTBraconeFPignatelliPCarnevaleRThe association between hypoalbuminemia and risk of death due to cancer and vascular disease in individuals aged 65 years and older: Findings from the prospective Moli-sani cohort studyEClinicalMedicine72102627202410.1016/j.eclinm.2024.10262739010980 ShapaerTChenYPanYWuZTangTZhaoZZengXElevated BEAN1 expression correlates with poor prognosis, immune evasion, and chemotherapy resistance in rectal adenocarcinomaDiscov Oncol15446202410.1007/s12672-024-01321-539276259 ZouYHuXDengXDistant lymph node metastases from breast cancer-Is it time to review TNM cancer staging?JAMA Netw Open4e212026202110.1001/jamanetworkopen.2021.202633724385 VeerlaSHohmannLNacerDFVallon-ChristerssonJStaafJPerturbation and stability of PAM50 subtyping in population-based primary invasive breast cancerNPJ Breast Cancer983202310.1038/s41523-023-00589-037857634 ZhangHXiaTXiaZZhouHLiZWangWZhaiXJinBKIF18A inactivates hepatic stellate cells and alleviates liver fibrosis through the TTC3/Akt/mTOR pathwayCell Mol Life Sci8196202410.1007/s00018-024-05114-538372748 ZhaoHYuLWangLYinXLiuKLiuWLinSWangLIntegrated analysis of single-cell and bulk RNA sequencing data reveals immune-related lncRNA-mRNA prognostic signature in triple-negative breast cancerGenes Dis11571574202310.1016/j.gendis.2023.04.00637692501 Reyes-RuizACalvillo-RodriguezKMMartínez-TorresACRodríguez-PadillaCThe bovine dialysable leukocyte extract IMMUNEPOTENT CRP induces immunogenic cell death in breast cancer cells leading to long-term antitumour memoryBr J Cancer12413981410202110.1038/s41416-020-01256-y33531687 ShayimuPAwulaMWangCYJiapaerRPanYPWuZMChenYZhaoZLSerum nutritional predictive biomarkers and risk assessment for anastomotic leakage after laparoscopic surgery in rectal cancer patientsWorld J Gastrointest Surg1631423154202410.4240/wjgs.v16.i10.314239575267 HuaSWangWYaoZGuJZhangHZhuJXieZJiangHThe fatty acid-related gene signature stratifies poor prognosis patients and characterizes TIME in cutaneous melanomaJ Cancer Res Clin Oncol15040202410.1007/s00432-023-05580-738279987 ParkYRJeeWParkSMKimSWBaeHJungJHKimHKimSChungJSJangHJViscum album induces apoptosis by regulating STAT3 signaling pathway in breast cancer cellsInt J Mol Sci2411988202310.3390/ijms24151198837569363 HackerUTHasencleverDBaberRLinderNBusseHObermannovaRZdrazilova-DubskaLValikDLordickFModified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trialAnn Oncol33685692202210.1016/j.annonc.2022.03.27435395383 WuZChenYJiangDPanYTangTMaYShapaerTMitochondrial-related drug resistance lncRNAs as prognostic biomarkers in laryngeal squamous cell carcinomaDiscov Oncol15785202410.1007/s12672-024-01690-x39692950 MaLGaoPLiuZJiaoDLingRXiaoJZhaoYWangYYangHLiuYAssociation of a complete breast cancer pathologic response with axillary lymph node metastasis via neoadjuvant chemotherapy: Results from the CSBrS-012 studyChin Med J (Engl)13713691371202410.1097/CM9.000000000000284937882089 DimitrakopoulosFIGoussiaAKoliouGADadouliKBatistatouAKoureaHPBobosMArapantoni-DadiotiPTzaidaOKoletsaTTen-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytesBreast73103668202410.1016/j.breast.2023.10366838176305 ProctorMJTalwarDBalmarSMO'ReillyDSFoulisAKHorganPGMorrisonDSMcMillanDCThe relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome StudyBr J Cancer1038706201010.1038/sj.bjc.660585520717110 HaqATAYangPPJinCShihJHChenLMTsengHYChenYAWengYSWangLHSnyderMPImmunotherapeutic IL-6R and targeting the MCT-1/IL-6/CXCL7/PD-L1 circuit prevent relapse and metastasis of triple-negative breast cancerTheranostics1421672189202410.7150/thno.9292238505617 FarhanaAAlsrhaniAAlghshamRSDerafaWKhanYSRasheedZGold nanoparticles downregulate IL-6 expression/production by upregulating microRNA-26a-5p and deactivating the RelA and NF-κBp50 transcription pathways in activated breast cancer cellsInt J Mol Sci251404202410.3390/ijms2503140438338683 ChenYMaitiniyaziGLiZLiTLiuYZhangRCaoXGuDXiaSTNF-α mediates the association between dietary inflammatory index and depressive symptoms in breast cancerNutrients1584202210.3390/nu1501008436615742 RuanGTXieHLHuCLLiuCAZhangHYZhangQWangZWZhangXGeYZLinSQComprehensive prognostic effects of systemic inflammation and Insulin resistance in women with breast cancer with different BMI: A prospective multicenter cohortSci Rep134303202310.1038/s41598-023-31450-w36922570 GaoWLiMZhangYFibrinogen/albumin ratio (FAR) in patients with triple negative breast cancer and its relationship with epidermal growth factor receptor expressionOnco Targets Ther1454035415202110.2147/OTT.S33997334908845 XiangMZhangHTianJYuanYXuZChenJLow serum albumin levels and high neutrophil counts are predictive of a poorer prognosis in patients with metastatic breast cancerOncol Lett24432202210.3892/ol.2022.1355236311691 WangMDDuanFFHuaXCaoLXiaWChenJYA novel albumin-related nutrition biomarker predicts breast cancer prognosis in neoadjuvant chemotherapy: A two-center cohort studyNutrients154292202310.3390/nu1519429237836576 YinLDuanJJBianXWYuSCTriple-negative breast cancer molecular subtyping and treatment progressBreast Cancer Res2261202010.1186/s13058-020-01296-532517735

Kaplan-Meier survival curves for patients with breast cancer based on mGPS scores. The Kaplan-Meier survival curves display the OS of patients with breast cancer stratified by preoperative mGPS categories (mGPS 0, mGPS 1 and mGPS 2). The x-axis represents the follow-up time (in years), while the y-axis indicates the cumulative survival probability. Significant differences in survival were observed across the three groups, with higher mGPS scores associated with poorer survival outcomes (log-rank test, P<0.001). mGPS, modified Glasgow prognostic score; OS, overall survival.

Risk factors associated with mGPS. Forest plot displaying the results of logistic regression analysis identifying clinical and pathological risk factors associated with a higher mGPS. The x-axis represents the ORs for each variable, while the y-axis lists the clinical and pathological factors, including age, smoking status, TNM stage and PAM50 subtype. Error bars indicate the 95% CIs for each OR. mGPS, modified Glasgow prognostic score; CI, confidence interval; OR, odds ratio; BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor; TNBC, triple-negative breast cancer; PAM50, 50-gene intrinsic subtype classifier.

Multivariate Cox proportional hazards regression analysis of OS. The forest plot illustrates the HRs for OS based on multivariate Cox proportional hazards regression analysis. The x-axis represents the HRs, while the y-axis lists the clinical variables and mGPS. Variables included in the multivariate analysis were adjusted for potential confounders. Significant predictors of OS included mGPS, age, smoking and TNM stage (P<0.05). OS, overall survival; HR, hazard ratio; BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor; mGPS, modified Glasgow prognostic score.

Nomogram for predicting 5- and 10-year OS. (A) A nomogram developed using multivariate Cox regression analysis incorporates age, smoking status, TNM stage, PAM50 subtype and mGPS to predict 5- and 10-year OS. Each variable is assigned a score, which is summed to estimate survival probabilities. (B) Calibration curves validate the predictive accuracy of the nomogram by comparing the predicted OS probabilities with observed outcomes. The dashed diagonal line represents perfect agreement and the solid lines indicate the calibration results for the model. The blue crosses represent individual patient data-points, showing the comparison between predicted and observed overall survival probabilities. OS, overall survival; mGPS, modified Glasgow prognostic score; ER, estrogen receptor; PR, progesterone receptor; TNBC, triple-negative breast cancer; HER2, human EGFR 2; TNM, tumor-node-metastasis; PAM50, 50-gene intrinsic subtype classifier.

Distribution of patients with breast cancer based on mGPS.

mGPS CRP, mg/l Alb, g/l Number
Low (0) ≤10 ≥35 108
High
  1 >10 ≥35 120
  2 >10 <35 72

mGPS, modified Glasgow prognostic score; CRP, C-reactive protein; Alb, albumin.

Baseline characteristics of patients with breast cancer stratified by mGPS scores.

High mGPS
Characteristic Total (n=300) Low mGPS 0 (n=108)
1 (n=120) 2 (n=72) P-value
Age, years <0.001
  <65 186 84 67 35
  ≥65 114 24 53 37
BMI, kg/m2 0.011
  ≤18.5 83 24 29 30
  >18.5, <25 142 61 54 27
  ≥25 75 23 37 15
Smoking 167 42 75 50 <0.001
Drinking 208 65 87 56 0.027
Diabetes 74 15 37 22 0.026
Hypertension 136 43 58 35 0.354
Family history 45 13 22 10 0.395
TNM stage 0.001
  I 159 72 63 24
  II 94 28 36 30
  III 35 7 15 13
  IV 12 1 6 5
PAM50 0.047
  ER+ or PR+ 151 62 56 33
  HER2+ 82 29 38 15
  TNBC 67 17 26 24
Treatment
  Endocrine therapy 155 62 59 34 0.317
  Targeted therapy 84 30 38 16 0.369
  Chemotherapy 102 36 37 29 0.402
  Immunotherapy 44 14 21 9 0.525

mGPS, modified Glasgow prognostic score; TNM, tumor-node-metastasis; BMI, body mass index; PAM50, 50-gene intrinsic subtype classifier; ER, estrogen receptor; PR, progesterone receptor; TNBC, triple-negative breast cancer; HER2, human EGFR 2.

Univariate analysis of risk factors associated with high mGPS scores.

Characteristic OR 95% CI univariate analysis P-value
Age (≥65 vs. <65 years) 2.836 1.783–4.545 <0.001
BMI 0.874 0.143–2.522 0.068
Smoking 3.214 1.948–5.267 <0.001
Drinking 2.180 1.355–3.486 0.002
Diabetes 1.357 0.268–2.641 0.312
Hypertension 1.851 1.129–3.525 0.761
Family history 2.536 1.263–3.248 0.137
TNM stage (I as reference)
  II 1.512 1.051–2.274 1.106
  III 3.145 1.358–5.765 <0.001
  IV 4.832 3.227–8.906 <0.001
PAM50
(ER+ or PR+ as reference)
  HER2+ 0.928 0.403–1.275 2.004
  TNBC 3.123 1.858–5.251 <0.001

OR, odds ratio; CI, confidence interval; TNM, tumor-node-metastasis; BMI, body mass index; PAM50, 50-gene intrinsic subtype classifier; ER, estrogen receptor; PR, progesterone receptor; TNBC, triple-negative breast cancer; HER2, human EGFR 2.

Univariate Cox proportional hazards regression analysis of overall survival.

Characteristic Total (n) HR (95% CI) univariate analysis P-value
Age 300 3.376 (1.227–5.258) <0.001
BMI 300 0.539 (0.364–2.136) 0.132
Smoking 300 2.045 (1.183–4.904) 0.001
Drinking 300 1.762 (1.254–3.255) 0.004
Diabetes 300 3.318 (0.798–6.527) 0.003
Hypertension 300 2.434 (1.218–4.663) 1.672
Family history 300 1.827 (1.374–3.359) 0.025
TNM stage 300
  I 159 Reference
  II 94 1.268 (1.035–2.186) 3.846
  III 35 2.659 (1.517–5.043) 0.031
  IV 12 4.274 (2.654–7.268) <0.001
PAM50 300
  ER+ or PR+ 151 Reference
  HER2+ 82 0.792 (0.512–2.195) 5.415
  TNBC 67 3.053 (2.073–6.383) <0.001
mGPS 300
  0 108 Reference
  1 120 2.622 (1.674–5.538) 0.001
  2 72 4.139 (2.822–9.163) <0.001

HR, hazard ratio; CI, confidence interval; BMI, body mass index; TNM, tumor-node-metastasis; PAM50, 50-gene intrinsic subtype classifier; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; mGPS, modified Glasgow prognostic score.